EUVIMEDEUVIMED entdecken
Crossref

4117eP Patient-reported experience of switching from reference to biosimilar denosumab in oncology: A Canadian survey

K. Jerzak, Z. Hamilou, J. Leigh, S. Jagodic, S. Howe, A. Reinbold, B. Katzenberger

Annals of Oncology · 2026-12 · 37 · S2106

DOI: 10.1016/j.annonc.2026.08.4366 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Oncology, 2026-12. Verfasst von K. Jerzak und 6 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Jerzak, K., Hamilou, Z., Leigh, J., Jagodic, S., Howe, S., Reinbold, A., & Katzenberger, B. (2026). 4117eP Patient-reported experience of switching from reference to biosimilar denosumab in oncology: A Canadian survey. Annals of Oncology, 37, S2106. https://doi.org/10.1016/j.annonc.2026.08.4366

Vancouver

Jerzak K, Hamilou Z, Leigh J, Jagodic S, Howe S, Reinbold A, et al. 4117eP Patient-reported experience of switching from reference to biosimilar denosumab in oncology: A Canadian survey. Annals of Oncology. 2026;37:S2106. doi:10.1016/j.annonc.2026.08.4366

BibTeX
@article{Jerzak2026,
  author = {Jerzak, K. and Hamilou, Z. and Leigh, J. and Jagodic, S. and Howe, S. and Reinbold, A. and Katzenberger, B.},
  title = {4117eP Patient-reported experience of switching from reference to biosimilar denosumab in oncology: A Canadian survey},
  journal = {Annals of Oncology},
  year = {2026},
  volume = {37},
  pages = {S2106},
  doi = {10.1016/j.annonc.2026.08.4366}
}
Kostenlos starten →